Explain the Role of Vilobelimab, the Latest MAb for COVID-19

June 2023

A new emergency use authorization will put the spotlight on vilobelimab (Gohibic) to treat COVID-19 in hospitalized adults.

Vilobelimab blocks complement C5a...to reduce inflammation.

It’s only authorized to treat COVID-19 when started within 48 hours after beginning mechanical ventilation or extracorporeal membrane oxygenation (ECMO).

Get concise advice on drug therapy, plus unlimited access to CE

Hospital Pharmacist's Letter membership benefits include:

12 issues every year — what you need to know and do, right now
Quick, practical reference charts and tools
Comprehensive CE library to meet license renewal and state requirements
Multiple course formats including live webinars, podcasts, and CE-in-the-Letter to match your learning style
Plus much more!

Choose the right tier for your needs today.

Subscribe Today!

Already a subscriber? Log in

Volume pricing available. Get a quote

Liver Disease Guide Proper Use of Albumin
Antiplatelets Tailor DAPT Duration for Patients at High Bleeding Risk
COVID-19 Explain the Role of Vilobelimab, the Latest MAb for COVID-19
Med Safety Keep Your Eyes Open for Incorrect Labeling and Packaging
COVID-19 Navigate Ongoing COVID-19 Vaccine Changes
Med Adherence Consider Approaches to Improve Med Adherence
Dermatology Clarify the Role of OTC and Rx Options for Poison Ivy
Cholesterol Think “Lower Is Better” for LDL in Patients at High CV Risk
Med Safety Put Osteonecrosis of the Jaw Risk in Perspective

Explain the Role of Vilobelimab, the Latest MAb for COVID-19

Get concise advice on drug therapy, plus unlimited access to CE

Table of Contents